Taming vessels to treat cancer.
Jain
Rakesh K
RK
Radiation Oncology Department, Massachusetts General Hospital and Harvard Medical School, USA.
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001808:Blood Vessels / Q000473:pathology; D003131:Combined Modality Therapy; D006801:Humans; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D011878:Radiotherapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000276:immunology; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor